Resources

For health care professionals

Biosimilars in the EU: Information Guide for Healthcare Professionals

CADTH Biosimilar Drugs: Health care provider hand-out

FDA Biosimilars: Health care provider materials

Health Canada – Biosimilar biologic drugs in Canada: Fact Sheet

International Coalition of Medicines Regulatory Authorities – Biosimilars Statement

Pan-Canadian Oncology Biosimilars Initiative

- Biosimilars – What You Need to Know – for Providers
- Discussing Biosimilars with Patients: A Resource for Healthcare Providers
- Biologics and Biosimilars: Information for Healthcare Providers (Youtube)

Patients Experience Evidence Research (PEER) – Tools for Practice #236

Supporting evidence

CADTH International Policies on the Appropriate Use of Biosimilar Drugs


Drug Discontinuation in Studies Including a Switch from an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review

ECCO: Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease

Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice

Non-medical Switch from originator infliximab to biosimilar (rheumatology)

Non-medical switch from originator etanercept to biosimilar (rheumatology)
NOR-SWITCH study: non-medical switching for all indications, originator infliximab to biosimilar

NOR-SWITCH study: long-term follow-up after switching from originator infliximab to its biosimilar

Switching to Insulin Glargine Biosimilar

Similar efficacy and safety between insulin glargine biosimilar and biologic (Lantus)

Alberta College of Family Physicians Tools for Practice #236
CADTH Biosimilar Drugs: Health care provider hand-out

CADTH Biosimilar Drugs: Your Questions Answered

Canadian Family Physician – Biosimilars versus biologics for inflammatory conditions

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes


British Columbia Biosimilars Initiative

Biosimilars Initiative for Prescribers

Biosimilars Initiative FAQ for Pharmacists